Omadacycline for Mycobacterium abscessus lung infection
Part of Infections clinical trials.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed Mycobacterium abscessus lung infection (diagnosed by lab culture or genetic testing)
- You are 18 years of age or older
- You have complete medical records available for the study team to review
- You received treatment with omadacycline for at least one month
- You do not have a co-infection with other rare mycobacteria at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This study tests an investigational medication called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus bacteria. You may be able to join if your infection is stable enough to delay standard treatment and you have symptoms like cough, fatigue, or weight loss.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests a treatment using bacteriophages (viruses that attack specific bacteria) to fight a tough lung infection called Mycobacterium abscessus that doesn't respond to usual antibiotics. If you have this infection, this treatment might offer a new way to clear it.
This study tests if a drug called sitafloxacin can quickly kill mycobacterium abscessus bacteria in the lungs. It may help people with this hard-to-treat infection find a more effective treatment.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.